• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Novartis buys Ebewe injectables unit

Article

28 May 2009

Novartis AG has agreed to buy Ebewe Pharma's injectables unit for $1.2 billion in an all-cash transaction.

The deal excludes Ebewe's neurological products business but will enable Novartis to add generic cancer drugs to its offerings.

Ebewe, based in Austria, generated EUR 188 million in sales last year and EUR 53 million in operating profit.

www.ebewe.comwww.novartis.com

Recent Videos
Related Content
Nucala Significantly Reduces Moderate to Severe Exasperations in Chronic Obstructive Pulmonary Disease

Nucala Significantly Reduces Moderate to Severe Exasperations in Chronic Obstructive Pulmonary Disease

Don Tracy, Associate Editor
September 6th 2024
Article

Results from the MATINEE trial found that Nucala led to a statistically significant and clinically meaningful reduction in moderate/severe exacerbations of chronic obstructive pulmonary disease compared to placebo over 104 weeks.

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Beyond the Birthrate: The Societal Costs of Maternal Mortality

Miranda Schmalfuhs
September 6th 2024
Podcast

Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.

FDA Approves Boruzu for Subcutaneous, Intravenous Administration for Multiple Myeloma, Mantle Cell Lymphoma

FDA Approves Boruzu for Subcutaneous, Intravenous Administration for Multiple Myeloma, Mantle Cell Lymphoma

Don Tracy, Associate Editor
September 6th 2024
Article

Boruzu is the first ready-to-use version of bortezomib for subcutaneous and intravenous administration in the treatment of multiple myeloma and mantle cell lymphoma.

Empty Shelves, Urgent Solutions

Empty Shelves, Urgent Solutions

Miranda Schmalfuhs
August 5th 2024
Podcast

Michael Abrams, Managing Partner at Numerof & Associates discusses pharmacy deserts, alternative solutions to ensure continued access to medications for all Americans, potential long term consequences if these pharmacy closures continue, and more

Pharma Pulse 9/6/24: Gaps and Opportunities in Qualitative Systematic Reviews, Companies Grapple With Expanding Cyber Rules & more

Pharma Pulse 9/6/24: Gaps and Opportunities in Qualitative Systematic Reviews, Companies Grapple With Expanding Cyber Rules & more

Miranda Schmalfuhs
September 6th 2024
Article

The latest news for pharma industry insiders.

Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes

Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes

Don Tracy, Associate Editor
September 5th 2024
Article

Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.